MNPR
Monopar Therapeutics Inc.
Biotechnology
Market Cap$416M
5Y Perf.+62.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MNPR vs CLDX
Revenue, margins, valuation, and 5-year total return — side by side.
CLDX
Celldex Therapeutics, Inc.
Biotechnology
Market Cap$2.22B
5Y Perf.+1147.9%
MNPR vs CLDX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MNPR | CLDX |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $416M | $2.22B |
| Revenue (TTM) | $0.00 | $2M |
| Net Income (TTM) | $-19M | $-259M |
| Gross Margin | — | 100.0% |
| Operating Margin | — | -191.6% |
| Total Debt | $0.00 | $2M |
| Cash & Equiv. | $46M | $29M |
MNPR vs CLDX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MNPR
CLDX
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Monopar Therapeutic… (MNPR) | 100 | 162.2 | +62.2% |
| Celldex Therapeutic… (CLDX) | 100 | 1247.9 | +1147.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MNPR vs CLDX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MNPR leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Celldex Therapeutics, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
MNPR
Monopar Therapeutics Inc.
The Income Pick
MNPR carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.46
- Lower volatility, beta 1.46, current ratio 11.47x
- Beta 1.46, current ratio 11.47x
Best for: income & stability and sleep-well-at-night
CLDX
Celldex Therapeutics, Inc.
The Growth Play
CLDX is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth -78.6%, EPS growth -59.2%, 3Y rev CAGR -14.0%
- -43.3% 10Y total return vs MNPR's -52.9%
- +76.2% vs MNPR's +59.7%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MNPR | 1.9K% revenue growth vs CLDX's -78.6% |
| Quality / Margins | MNPR | 0.7% margin vs CLDX's -172.5% |
| Stability / Safety | MNPR | Beta 1.46 vs CLDX's 1.73 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CLDX | +76.2% vs MNPR's +59.7% |
| Efficiency (ROA) | MNPR | -24.8% ROA vs CLDX's -38.9%, ROIC -321.4% vs -35.2% |
MNPR vs CLDX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
MNPR vs CLDX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMNPRLAGGINGCLDX
CLDXCelldex Therapeutics,…
1leads
MNPRMonopar Therapeutics …
1leads
6 Total Categories
CATEGORYLEADERvs CLDXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CLDX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MNPR5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CLDX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
CLDX and MNPR operate at a comparable scale, with $2M and $0 in trailing revenue.
| Metric | MNPRMonopar Therapeut… | CLDXCelldex Therapeut… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $2M |
| EBITDAEarnings before interest/tax | -$20M | -$284M |
| Net IncomeAfter-tax profit | -$19M | -$259M |
| Free Cash FlowCash after capex | -$11M | -$213M |
| Gross MarginGross profit ÷ Revenue | — | +100.0% |
| Operating MarginEBIT ÷ Revenue | — | -191.6% |
| Net MarginNet income ÷ Revenue | — | -172.5% |
| FCF MarginFCF ÷ Revenue | — | -142.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -93.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -3.4% | -73.2% |
CLDX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — MNPR and CLDX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | MNPRMonopar Therapeut… | CLDXCelldex Therapeut… |
|---|---|---|
| Market CapShares × price | $416M | $2.2B |
| Enterprise ValueMkt cap + debt − cash | $370M | $2.2B |
| Trailing P/EPrice ÷ TTM EPS | -45.90x | -8.54x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 1477.19x |
| Price / BookPrice ÷ Book value/share | 13.03x | 4.20x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — MNPR and CLDX each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
MNPR leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
MNPR delivers a -25.7% return on equity — every $100 of shareholder capital generates $-26 in annual profit, vs $-42 for CLDX. On the Piotroski fundamental quality scale (0–9), MNPR scores 4/9 vs CLDX's 3/9, reflecting mixed financial health.
| Metric | MNPRMonopar Therapeut… | CLDXCelldex Therapeut… |
|---|---|---|
| ROE (TTM)Return on equity | -25.7% | -41.7% |
| ROA (TTM)Return on assets | -24.8% | -38.9% |
| ROICReturn on invested capital | -3.2% | -35.2% |
| ROCEReturn on capital employed | -53.3% | -44.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | — | 0.00x |
| Net DebtTotal debt minus cash | -$46M | -$27M |
| Cash & Equiv.Liquid assets | $46M | $29M |
| Total DebtShort + long-term debt | $0 | $2M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
MNPR leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — MNPR and CLDX each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MNPR five years ago would be worth $23,648 today (with dividends reinvested), compared to $12,201 for CLDX. Over the past 12 months, CLDX leads with a +76.2% total return vs MNPR's +59.7%. The 3-year compound annual growth rate (CAGR) favors MNPR at 132.0% vs CLDX's -0.0% — a key indicator of consistent wealth creation.
| Metric | MNPRMonopar Therapeut… | CLDXCelldex Therapeut… |
|---|---|---|
| YTD ReturnYear-to-date | -5.4% | +23.4% |
| 1-Year ReturnPast 12 months | +59.7% | +76.2% |
| 3-Year ReturnCumulative with dividends | +1148.6% | -0.1% |
| 5-Year ReturnCumulative with dividends | +136.5% | +22.0% |
| 10-Year ReturnCumulative with dividends | -52.9% | -43.3% |
| CAGR (3Y)Annualised 3-year return | +132.0% | -0.0% |
Evenly matched — MNPR and CLDX each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MNPR and CLDX each lead in 1 of 2 comparable metrics.
Risk & Volatility
MNPR is the less volatile stock with a 1.46 beta — it tends to amplify market swings less than CLDX's 1.73 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CLDX currently trades 93.1% from its 52-week high vs MNPR's 59.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MNPRMonopar Therapeut… | CLDXCelldex Therapeut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.46x | 1.73x |
| 52-Week HighHighest price in past year | $105.00 | $35.79 |
| 52-Week LowLowest price in past year | $28.40 | $17.85 |
| % of 52W HighCurrent price vs 52-week peak | +59.5% | +93.1% |
| RSI (14)Momentum oscillator 0–100 | 68.1 | 60.7 |
| Avg Volume (50D)Average daily shares traded | 173K | 985K |
Evenly matched — MNPR and CLDX each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates MNPR as "Buy" and CLDX as "Buy". Consensus price targets imply 90.6% upside for MNPR (target: $119) vs 35.1% for CLDX (target: $45).
| Metric | MNPRMonopar Therapeut… | CLDXCelldex Therapeut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $119.00 | $45.00 |
| # AnalystsCovering analysts | 13 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CLDX leads in 1 of 6 categories (Income & Cash Flow). MNPR leads in 1 (Profitability & Efficiency). 3 tied.
Best OverallMonopar Therapeutics Inc. (MNPR)Leads 1 of 6 categories
Loading custom metrics...
MNPR vs CLDX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MNPR or CLDX a better buy right now?
Analysts rate Monopar Therapeutics Inc.
(MNPR) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MNPR or CLDX?
Over the past 5 years, Monopar Therapeutics Inc.
(MNPR) delivered a total return of +136. 5%, compared to +22. 0% for Celldex Therapeutics, Inc. (CLDX). Over 10 years, the gap is even starker: CLDX returned -43. 3% versus MNPR's -52. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MNPR or CLDX?
By beta (market sensitivity over 5 years), Monopar Therapeutics Inc.
(MNPR) is the lower-risk stock at 1. 46β versus Celldex Therapeutics, Inc. 's 1. 73β — meaning CLDX is approximately 18% more volatile than MNPR relative to the S&P 500.
04Which is growing faster — MNPR or CLDX?
On earnings-per-share growth, the picture is similar: Celldex Therapeutics, Inc.
grew EPS -59. 2% year-over-year, compared to -134. 5% for Monopar Therapeutics Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MNPR or CLDX?
Monopar Therapeutics Inc.
(MNPR) is the more profitable company, earning 0. 0% net margin versus -172. 5% for Celldex Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MNPR leads at 0. 0% versus -191. 6% for CLDX. At the gross margin level — before operating expenses — CLDX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MNPR or CLDX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MNPR or CLDX better for a retirement portfolio?
For long-horizon retirement investors, Monopar Therapeutics Inc.
(MNPR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Celldex Therapeutics, Inc. (CLDX) carries a higher beta of 1. 73 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MNPR: -52. 9%, CLDX: -43. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MNPR and CLDX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.